placebo over 52 weeks Efficacy observed both as monotherapy or combined with antifibrotics Well-tolerated, reduced death risk, though did not show statistically significant survival benefit Why it matters: Anti-inflammatory mechanism differentiates JASCAYD from existing antifibrotics (nintedanib, pirfenidone) Reinforces Boehringers leadership in respiratory innovation and re-energizes IPF R&D after years of limited breakthroughs Follow our page for more such updates: News Source: #FDAApproval #IPF #PulmonaryFibrosis #Respiratory #RespiratoryMedicine #DrugDevelopment #BoehringerIngelheim #Ofev #Esbriet #PharmaInnovation To view or add a comment, sign in Neuren today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for NNZ-2591 for the treatment of Phelan-McDermid syndrome (PMS)
Hybio's commercial momentum around GLP-1 APIs is accelerating rapidly
Previous research has found that activating GLP-1 receptors in rats brain causes the animals to eat less of a high-sugar chow, which they would normally prefer over a less delicious but healthier bland meal when given the option
Uno de los efectos buscados para tratar la obesidad y la prdida de kilos
doi: 10.1016/j.biopha.2021.111778 45 RemelyMHippeBZannerJAumuellerEBrathHHaslbergerG
(2024) Semaglutide and cardiovascular outcomes in obesity without diabetes: Results from the SELECT trial, Journal of the American College of Cardiology, 84(10), pp
